Tyme (TYME) Form 4 TYME / Barbara Galaini ownership change

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:	3235-0287
Estimated average burden
hours per response:	0.5

X

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

Galaini Barbara

(Last) (First) (Middle)

C/O TYME TECHNOLOGIES, INC.

1 PLUCKEMIN WAY - SUITE 103

(Street)

BEDMINSTER NJ 07921

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
TYME TECHNOLOGIES, INC. [ TYME ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
See remarks

3. Date of Earliest Transaction (Month/Day/Year)
09/16/2022

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/16/2022		D		258,300	D	(1)	0	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option - Option to buy	$2.25	09/16/2022		D			200,000	(2)	03/22/2028	Common Stock	200,000	(2)	0	D
Employee Stock Option - Option to buy	$2.25	09/16/2022		D			50,000	(3)	11/07/2023	Common Stock	50,000	(3)	0	D
Employee Stock Option - Option to buy	$1.56	09/16/2022		D			179,700	(4)	05/02/2029	Common Stock	179,700	(4)	0	D
Employee Stock Option - Option to buy	$1.39	09/16/2022		D			225,000	(5)	05/06/2030	Common Stock	225,000	(5)	0	D
Employee Stock Option - Option to buy	$1.43	09/16/2022		D			280,000	(6)	06/13/2031	Common Stock	280,000	(6)	0	D
Employee Stock Option - Option to buy	$0.32	09/16/2022		D			258,300	(7)	04/21/2032	Common Stock	258,300	(7)	0	D

Explanation of Responses:

1. Disposed of pursuant to the merger agreement between the issuer and Syros Pharmaceuticals, Inc. ("Syros") in exchange for 11,318 shares of Syros common stock having a market value of $7.30 per share at the close of trading on September 15, 2022, the last trading day immediately preceding the effective time of the merger, but after giving effect to a 1-for-10 reverse stock split by Syros (the "Reverse Split"), with cash paid in lieu of fractional shares.

2. This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 8,764 shares of Syros common stock for $51.35 per share, after giving effect to the Reverse Split.

3. This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 2,191 shares of Syros common stock for $51.35 per share, after giving effect to the Reverse Split.

4. This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 7,874 shares of Syros common stock for $35.60 per share, after giving effect to the Reverse Split.

5. This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 9,859 shares of Syros common stock for $31.72 per share, after giving effect to the Reverse Split.

6. This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 12,269 shares of Syros common stock for $32.63 per share, after giving effect to the Reverse Split.

7. This option was fully vested and assumed by Syros in the merger and replaced with an option to purchase 11,318 shares of Syros common stock for $7.30 per share, after giving effect to the Reverse Split.

Remarks:

Principal Accounting Officer and Controller

	By: /s/ Richard Cunningham as attorney-in-fact for Barbara Galaini	09/16/2022
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.